Abstract
In this issue of Blood, Roberts et al expand our understanding of prognostic biomarkers predicting the duration of remission in relapsed/refractory chronic lymphocytic leukemia (CLL) treated with venetoclax.
Cite
CITATION STYLE
APA
Rossi, D. (2019, July 11). Quest of biomarkers for venetoclax-treated CLL. Blood. American Society of Hematology. https://doi.org/10.1182/blood.2019001189
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free